Enliven Therapeutics Total Liabilities

Enliven Therapeutics (ELVN) currently reports a total liabilities of $20M as of September 2026. That compares with $15M in the prior-year period — up 37.5% year over year. Use the charts on this page to explore Enliven Therapeutics's total liabilities history and peer comparisons.

Enliven Therapeutics's total liabilities increased from $15M to $20M — a 37.5% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enliven Therapeutics reported $20M in total liabilities as of September 2026. That compares with $15M in the prior-year period — up 37.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Enliven Therapeutics, and consider following ELVN for alerts when major investors trade the stock.

Enliven Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ELVN with unrelated industries.